OBJECTIVE: Serotonergic dysfunction is considered to be involved in the pathophysiology of borderline personality disorder (BPD). The aim of this study was to investigate serotonin transporter availability in patients with BPD as a marker of the central serotonergic system. METHODS: Eight unmedicated patients with BPD and 9 healthy control subjects received single photon emission computed tomography (SPECT) 4 hours after injection of 185 MBq [I-123] ADAM (2-([2-([dimethylamino]methyl)phenyl]thio)). As a measure of brain serotonin transporter (SERT) availability, ratios of specific-to-nonspecific [I-123] ADAM binding for the brainstem and hypothalamus were calculated with an occipital reference. Levels of impulsiveness and depressive symptoms were assessed with the Barratt Impulsiveness Scale and the Beck Depression Inventory. RESULTS: Mean specific-to-nonspecific ratios showed a 43% higher brainstem and a 12% higher hypothalamus ADAM binding in patients, compared with control subjects. We found significant correlations of ADAM binding with both age and impulsiveness but not depression. Associations of BIS scores with ADAM binding remained significant after controlling for age and depression (r = 0.69, p < 0.01). CONCLUSION: The study provides evidence of a serotonergic dysfunction in patients with BPD and suggests a serotonergic component in the pathophysiology of the disorder. SERT binding reflected the level of impulsiveness as a common feature in BPD.
OBJECTIVE: Serotonergic dysfunction is considered to be involved in the pathophysiology of borderline personality disorder (BPD). The aim of this study was to investigate serotonin transporter availability in patients with BPD as a marker of the central serotonergic system. METHODS: Eight unmedicated patients with BPD and 9 healthy control subjects received single photon emission computed tomography (SPECT) 4 hours after injection of 185 MBq [I-123] ADAM (2-([2-([dimethylamino]methyl)phenyl]thio)). As a measure of brain serotonin transporter (SERT) availability, ratios of specific-to-nonspecific [I-123] ADAM binding for the brainstem and hypothalamus were calculated with an occipital reference. Levels of impulsiveness and depressive symptoms were assessed with the Barratt Impulsiveness Scale and the Beck Depression Inventory. RESULTS: Mean specific-to-nonspecific ratios showed a 43% higher brainstem and a 12% higher hypothalamus ADAM binding in patients, compared with control subjects. We found significant correlations of ADAM binding with both age and impulsiveness but not depression. Associations of BIS scores with ADAM binding remained significant after controlling for age and depression (r = 0.69, p < 0.01). CONCLUSION: The study provides evidence of a serotonergic dysfunction in patients with BPD and suggests a serotonergic component in the pathophysiology of the disorder. SERT binding reflected the level of impulsiveness as a common feature in BPD.
Authors: Andrew E Skodol; John G Gunderson; Bruce Pfohl; Thomas A Widiger; W John Livesley; Larry J Siever Journal: Biol Psychiatry Date: 2002-06-15 Impact factor: 13.382
Authors: J Tauscher; W Pirker; M Willeit; M de Zwaan; U Bailer; A Neumeister; S Asenbaum; C Lennkh; N Praschak-Rieder; T Brücke; S Kasper Journal: Biol Psychiatry Date: 2001-02-15 Impact factor: 13.382
Authors: J K Staley; S Krishnan-Sarin; S Zoghbi; G Tamagnan; M Fujita; J P Seibyl; P K Maciejewski; S O'Malley; R B Innis Journal: Synapse Date: 2001-09-15 Impact factor: 2.562
Authors: Julia Sacher; Susanne Asenbaum; Nikolas Klein; Thomas Geiss-Granadia; Nilufar Mossaheb; Christian Poetzi; Trawat Attarbaschi; Rupert Lanzenberger; Christoph Spindelegger; Alexander Rabas; Georg Heinze; Robert Dudczak; Siegfried Kasper; Johannes Tauscher Journal: Int J Neuropsychopharmacol Date: 2006-02-17 Impact factor: 5.176
Authors: Kelly P Cosgrove; Julie K Staley; Ronald M Baldwin; Frederic Bois; Christophe Plisson; Mohammed S Al-Tikriti; John P Seibyl; Mark M Goodman; Gilles D Tamagnan Journal: Nucl Med Biol Date: 2010-05-06 Impact factor: 2.408
Authors: Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère Journal: Eur J Nucl Med Mol Imaging Date: 2014-05-08 Impact factor: 9.236
Authors: Anna-Maria Kasparbauer; Dan Rujescu; Michael Riedel; Oliver Pogarell; Anna Costa; Thomas Meindl; Christian la Fougère; Ulrich Ettinger Journal: Neuropsychopharmacology Date: 2014-09-15 Impact factor: 7.853
Authors: Vasileios Boulougouris; Ioannis Malogiannis; George Lockwood; Iannis Zervas; Giuseppe Di Giovanni Journal: Exp Brain Res Date: 2013-08-23 Impact factor: 1.972
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944
Authors: Anke J Borgers; Anneke Alkemade; Elsmarieke M Van de Giessen; Madeleine L Drent; Jan Booij; Peter H Bisschop; Eric Fliers Journal: EJNMMI Res Date: 2013-04-25 Impact factor: 3.138